Get the Stockscreener App
44.72
0.32%
0.055
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $44.72, with a volume of 3.79M.
It is up +0.32% in the last 24 hours and down -4.10% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$44.66
Open:
$44.74
24h Volume:
3.79M
Relative Volume:
0.28
Market Cap:
$91.01B
Revenue:
$47.70B
Net Income/Loss:
$5.07B
P/E Ratio:
18.04
EPS:
2.4784
Net Cash Flow:
$14.58B
1W Performance:
-5.53%
1M Performance:
-4.10%
6M Performance:
-15.57%
1Y Performance:
-14.62%
1-Day Range:
$44.45
$44.90
1-Week Range:
$44.25
$47.41
52-Week Range:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
44.72 | 90.90B | 47.70B | 5.07B | 14.58B | 2.4784 |
|
LLY
Lilly Eli Co
|
848.43 | 756.28B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
189.07 | 454.91B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
231.23 | 411.31B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.60 | 254.66B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.66 | 218.83B | 63.43B | 16.42B | 14.72B | 6.4861 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Abel Hall LLC Has $444,000 Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Shell Asset Management Co. Raises Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Kingswood Wealth Advisors LLC - MarketBeat
Cell Therapy Market Set for Dynamic Growth with Key Players Bristol Myers Squibb Company, Amgen Inc. - industrytoday.co.uk
Bristol Myers Squibb 2025: Rewiring the company - PharmaLive
Bristol Myers Squibb Company $BMY Shares Sold by Grimes & Company Inc. - MarketBeat
Ameriflex Group Inc. Lowers Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Investing Smart: Bristol-Myers Squibb (BMY) Among the Best Affordable Dividend Stocks - Yahoo
Bristol Myers Squibb Company $BMY Shares Sold by QRG Capital Management Inc. - MarketBeat
Bristol Myers Squibb Stock Hits Day High with Strong Intraday Performance - Markets Mojo
Fairvoy Private Wealth LLC Sells 18,895 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by J. Safra Sarasin Holding AG - MarketBeat
Quattro Financial Advisors LLC Sells 19,600 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
How Bristol Myers Squibb Company (BRM) stock performs during market turbulenceRisk Management & Fast Moving Market Watchlists - newser.com
Mirae Asset Global Investments Co. Ltd. Grows Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery - Insider Monkey
Cliftonlarsonallen Wealth Advisors LLC Buys New Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Layoff Tracker: CSL Vifor, Bolt Cut Staff - BioSpace
PTAB Condemns Bristol-Myers' 'Whac-A-Mole Strategy' - Law360
11 Best Affordable Dividend Stocks to Buy Now - Insider Monkey
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap - Benzinga
Bristol-Myers retirees win round in lawsuit over $2B Athene annuity deal - InsuranceNewsNet
Bristol Myers Alzheimer's Drug Earns FDA Fast Track - Yahoo
PRT Case Against Bristol-Myers Squibb to Proceed - planadviser
Janney Montgomery Scott LLC Sells 273,099 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Co (BMY) Stock Price, Trades & News - GuruFocus
Bristol-Myers Squibb (BMY) Reports Strong Multiple Myeloma Data - Insider Monkey
Bristol-Myers Squibb Company (BMY) Begins Selling Its Psoriasis Medication Sotyktu Directly to Cash-Paying U.S. Customers - Insider Monkey
Judge Lets Core Claims Proceed in PRT Case Against Bristol-Myers Squibb - plansponsor
FDA grants fast track designation for Alzheimer’s drug BMS-986446 - Investing.com India
Major Alzheimer's Breakthrough: BMS-Prothena Drug Gets FDA Fast Track for Targeting Tau Protein - Stock Titan
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Why Is Bristol-Myers Squibb (BMY) Stock Rocketing Higher Today - Yahoo Finance
Ex-Dividend Reminder: Quest Diagnostics, Bristol Myers Squibb and Globe Life - Nasdaq
Bristol Myers (BMY) Receives Fast Track Status for Alzheimer's T - GuruFocus
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
FDA grants fast track designation for Bristol Myers Squibb’s Alzheimer’s drug - Investing.com Nigeria
Bristol Myers Squibb (BMY) Joins Consortium for AI Drug Discover - GuruFocus
BMYBristol-Myers Squibb Co Latest Stock News & Market Updates - Stock Titan
Big pharma firms announce direct-to-consumer sales and price cuts in U.S. - Reuters
Lbp Am Sa Cuts Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers, Takeda to pool data for AI-based drug discovery By Reuters - Investing.com
Columbia Asset Management Sells 90,600 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers, Takeda to pool data for AI-based drug discovery - Yahoo
Park Place Capital Corp Lowers Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Judge denies motions by Bristol-Myers Squibb, State Street IM to dismiss PRT lawsuit - Pensions & Investments
Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Bernstein Maintains a Hold on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb call volume above normal and directionally bullish - TipRanks
Multiple Modalities in the Oncology Market Size, Regional Growth and Trends - GlobeNewswire Inc.
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):